L

Lionco Pharmaceutical Group Co Ltd
SSE:603669

Watchlist Manager
Lionco Pharmaceutical Group Co Ltd
SSE:603669
Watchlist
Price: 4.99 CNY -1.58% Market Closed
Market Cap: 3.6B CNY

Lionco Pharmaceutical Group Co Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Lionco Pharmaceutical Group Co Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
L
Lionco Pharmaceutical Group Co Ltd
SSE:603669
Pre-Tax Income
-ÂĄ114.5m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Pre-Tax Income
ÂĄ5.7B
CAGR 3-Years
20%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Pre-Tax Income
ÂĄ2.8B
CAGR 3-Years
-1%
CAGR 5-Years
8%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Pre-Tax Income
ÂĄ8.5B
CAGR 3-Years
40%
CAGR 5-Years
5%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Pre-Tax Income
ÂĄ6.3B
CAGR 3-Years
28%
CAGR 5-Years
2%
CAGR 10-Years
7%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Pre-Tax Income
ÂĄ4B
CAGR 3-Years
N/A
CAGR 5-Years
218%
CAGR 10-Years
N/A
No Stocks Found

Lionco Pharmaceutical Group Co Ltd
Glance View

Market Cap
3.6B CNY
Industry
Pharmaceuticals

Lionco Pharmaceutical Group Co., Ltd. engages in the sale of chemical drug and antibiotic agents. The company is headquartered in Shannan, Xizang and currently employs 678 full-time employees. The company went IPO on 2015-05-28. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The firm's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The firm operates its business in domestic market.

Intrinsic Value
2.71 CNY
Overvaluation 46%
Intrinsic Value
Price
L

See Also

What is Lionco Pharmaceutical Group Co Ltd's Pre-Tax Income?
Pre-Tax Income
-114.5m CNY

Based on the financial report for Sep 30, 2025, Lionco Pharmaceutical Group Co Ltd's Pre-Tax Income amounts to -114.5m CNY.

What is Lionco Pharmaceutical Group Co Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 3Y
-9%

Over the last year, the Pre-Tax Income growth was -11%. The average annual Pre-Tax Income growth rates for Lionco Pharmaceutical Group Co Ltd have been -9% over the past three years .

Back to Top